TORONTO, CANADA — (June 7, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, today announced its participation in the following U.S.-based virtual investor conferences in June:
2021 LD Micro Invitational XI, Live company presentation by Scott Curtis, Executive VP, and Dr. Joseph Stauffer, Chief Medical Officer, on Wednesday, June 9, 2021 at 12:30 pm (Eastern Time).
Raymond James Human Health Innovation Conference, Live company presentation by Dan Legault, CEO, and Dr. Joseph Stauffer on Wednesday, June 23, 2021 at 8:40 am (Eastern Time).
A link to the webcast of each event will be available on the News and Events section of the Company’s website at antibethera.com. Following the presentations, a replay of the webcasts will be available on the website for 90 days.
About Antibe Therapeutics Inc.
Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions. The Company’s current pipeline includes three assets that seek to overcome the gastrointestinal (“GI”) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (“NSAIDs”). Antibe’s lead drug, otenaproxesul, is entering Phase III for the treatment of osteoarthritis pain. Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-protective alternative to low-dose aspirin. The Company’s next target is inflammatory bowel disease (“IBD”), a condition long in need of safer, more effective therapies. Learn more at antibethera.com.
Antibe Therapeutics Inc.
VP Investor Relations
Read all news